# Sermorelin dosage: what the studies used · PepVault guides

Source: https://pepvault.app/guides/sermorelin-dosage-in-studies

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [The science](https://pepvault.app/guides#science)

# Sermorelin dosage: what the studies used

Reviewed November 2026 16 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Sermorelin dosage in studies: 1 mcg/kg IV for testing, 30 mcg/kg nightly in children, 0.5 to 2 mg in older men. How it works and what users report.

- **Last reviewed:** Nov 18, 2026
- **Sources:** 16
- **Questions:** 8
- **Compounds:** 3

## The short answer

Studies dosed sermorelin by purpose. As a one-time test of the pituitary, it was given at 1 mcg/kg by IV. In a 110-child growth trial, the dose was 30 mcg/kg under the skin once daily at bedtime, for up to a year. Studies in older men used 0.5 to 2 mg, twice daily or nightly, for 2 to 6 weeks. These are research figures, not a dose for anyone.

Every number checked at its primary source · Nov 18, 2026 · [16 sources](https://pepvault.app/guides/sermorelin-dosage-in-studies#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Human studies, mostly from the 1990s: one large open-label trial in children with growth hormone deficiency, small, short studies in older adults (19 people at most) and one 2017 chart review.

## What is sermorelin?

Sermorelin is a shortened copy of the body's own signal for growth hormone. That signal, growth hormone-releasing hormone (GHRH), is a chain of 44 amino acids that the hypothalamus releases to tell the pituitary to make growth hormone[16](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-16). Sermorelin keeps only the first 29 links of the chain, and those 29 are the shortest synthetic stretch that carries the full activity of the whole hormone[1](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-1).

Unlike most peptides people track, it had a real career as an FDA-approved drug, sold as Geref. The FDA approved a 0.05 mg ampule on December 28, 1990, for testing whether the pituitary can release growth hormone, and 0.5 mg and 1 mg vials on September 26, 1997, to treat children with idiopathic growth hormone deficiency and growth failure[9](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-9) [10](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-10) [11](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-11).

The maker, EMD Serono, told the FDA in 2008 that it was discontinuing both products, and the approvals were withdrawn effective June 18, 2009. In 2013 the FDA reviewed its records, the literature and the post-marketing adverse event data, and determined that Geref was not withdrawn from sale for reasons of safety or effectiveness[9](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-9).

[Peptide Sky See Sermorelin as a molecule 53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists. Open the Peptide Sky](https://pepvault.app/lab/sky)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How does sermorelin work?

It does the hypothalamus's job. Sermorelin binds the GHRH receptor on the growth hormone-making cells of the anterior pituitary, and those cells release their own growth hormone, which in turn raises IGF-1[1](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-1) [12](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-12). Because it acts one step upstream, the body's brakes still apply: somatostatin and the feedback from IGF-1 keep shaping how much is released[12](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-12). That is the main difference from injecting growth hormone itself. In the words of one trial team, describing earlier studies in children and young adults, GHRH raises GH and IGF-1 "while preserving physiological GH release"[3](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-3).

The molecule is gone from the blood within minutes, and its effect lasts hours. In 10 healthy men given GHRH(1-29) by IV infusion, its disappearance half-time was about 4 minutes[7](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-7). Yet after a single IV dose, growth hormone stayed raised for about 3 hours[6](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-6), and in a nightly trial of a close variant, the release began within 10 minutes and lasted about 2 hours[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5).

That short life is why the studies dose it once or more a day, and why its relatives were built. CJC-1295, in its version with DAC, is a long-acting GHRH analog with an estimated half-life of 5.8 to 8.1 days, and the report of its trials in healthy adults opens by noting that GHRH's therapeutic use "is limited by its short duration of action"[14](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-14). Tesamorelin, another GHRH analog, is FDA-approved, as Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy[15](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-15).

## What doses were used in sermorelin studies?

The dose tracked the job. A test needed one small IV dose; treatment needed a daily injection under the skin, at about 30 times the weight-based amount. Here is each study, who was in it and what it used.

| Study | Who | Dose and route | How often, how long |
| --- | --- | --- | --- |
| Diagnostic test[1](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-1) | Children being tested for growth hormone deficiency | 1 mcg/kg by IV | Once |
| Dose-finding, 1993[6](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-6) | 30 healthy men aged 19 to 43 | From 0.25 mcg/kg by IV; the largest GH release came at 1 to 2 mcg/kg | Single doses |
| Children's growth trial, 1996[2](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-2) | 110 children with GH deficiency, before puberty and not treated before | 30 mcg/kg under the skin | Once daily at bedtime, up to 1 year |
| Older men, 1992[3](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-3) | 10 healthy men, average age 68 | 0.5 mg and 1 mg under the skin | Twice daily, 14 days at each dose |
| Older men, 1997[4](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-4) | 11 healthy men aged 64 to 76 | 2 mg under the skin | Nightly, 6 weeks |
| Older adults, 1997[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5) | 10 women and 9 men aged 55 to 71, given a close variant | 10 mcg/kg under the skin | Nightly at 9 pm, 16 weeks |
| Clinic chart review, 2017[13](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-13) | 14 men on testosterone, average age 33 | 100 mcg of sermorelin, GHRP-2 and GHRP-6, as prescribed | Three times daily, about 134 days on average |

The doses in the table are what each study used. They describe the research, not a protocol to copy. The 1997 trial of older adults used [Nle27]GHRH(1-29), which differs from sermorelin at one of its 29 positions[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5) [16](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-16).

Why so much more under the skin than by IV? One clue is breakdown on the way in. In anaesthetized rats, the total amount of the peptide reaching the circulation after an injection under the skin was estimated at only 4% of that after an IV injection, and the authors pointed to breakdown at the injection site or on the way into the blood[8](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-8). That measurement is in rats; the human figure may differ.

## With this guide

### Sermorelin

- [Sermorelin: the full reference](https://pepvault.app/peptides/sermorelin)
- [Sermorelin dose guide](https://pepvault.app/lab/dosage/sermorelin)

### CJC-1295 with DAC

- [CJC-1295 with DAC: the full reference](https://pepvault.app/peptides/cjc-1295-with-dac)
- [CJC-1295 with DAC dose guide](https://pepvault.app/lab/dosage/cjc-1295-with-dac)

### Mixing charts

- [Sermorelin 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/sermorelin-5mg)
- [CJC-1295 with DAC 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cjc-1295-with-dac-10mg)
- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)

### Studies

- [CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adults](https://pepvault.app/research/cjc-1295-with-dac-teichman-2006)
- [CJC-1295 with DAC changed serum protein patterns in healthy men](https://pepvault.app/research/cjc-1295-with-dac-sackmann-sala-2009)
- [CJC-1295 with DAC: trough GH up 7.5-fold, pulses kept in healthy men](https://pepvault.app/research/cjc-1295-with-dac-ionescu-2006)
- [All 5 studies](https://pepvault.app/research#cjc-1295-with-dac)

### Compared with

- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Sermorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-sermorelin)
- [CJC-1295 no DAC vs Sermorelin](https://pepvault.app/peptides/compare/cjc-1295-no-dac-vs-sermorelin)
- [HGH vs Sermorelin](https://pepvault.app/peptides/compare/hgh-vs-sermorelin)
- [CJC-1295 with DAC vs CJC-1295 no DAC](https://pepvault.app/peptides/compare/cjc-1295-with-dac-vs-cjc-1295-no-dac)
- [CJC-1295 with DAC vs Ipamorelin](https://pepvault.app/peptides/compare/cjc-1295-with-dac-vs-ipamorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Growth hormone path

- [Tesamorelin and visceral fat: the approved use and the trials](https://pepvault.app/guides/tesamorelin-and-visceral-fat)
- [HGH dosage: what the labels and the trials used](https://pepvault.app/guides/hgh-dosage-labels-and-trials)
- [Tesamorelin vs retatrutide for belly fat](https://pepvault.app/guides/tesamorelin-vs-retatrutide)
- [AOD-9604: what the human trials found](https://pepvault.app/guides/aod-9604-trials)
- [Can you drink alcohol on growth hormone peptides?](https://pepvault.app/guides/gh-peptides-and-alcohol)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Vial](https://pepvault.app/glossary/vial)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [Growth hormone (GH)](https://pepvault.app/glossary/growth-hormone)
- [GHRH](https://pepvault.app/glossary/ghrh)
- [Discontinued (Drugs@FDA)](https://pepvault.app/glossary/discontinued)

## What did the studies find?

**In children**, the 1996 trial is the largest. Average growth speed rose from 4.1 cm a year before treatment to 8.0 cm a year at 6 months and 7.2 cm a year at 12 months, and 74% of the children had a good response at 6 months. Bone age did not run ahead of height, and IGF-1 did not overshoot[2](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-2). Data from a few children suggest the effect held for 36 months of continued treatment. As of the 1999 review, the once-daily schedule had not been compared head to head with growth hormone; when the same daily amount of sermorelin was given as an infusion or in three doses, growth speed rose less than with once-daily growth hormone injections[1](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-1).

**In older men**, the 1992 study found that the 1 mg twice-daily dose raised 24-hour growth hormone and IGF-1 until they no longer differed significantly from the young men in the study; the significant rises came only at that higher dose. Fasting glucose, blood pressure and routine blood tests did not change[3](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-3). The 1997 study of a single nightly 2 mg dose raised nighttime growth hormone but not IGF-1, improved two of six strength measures and an endurance test, and left body composition unchanged. Its authors concluded that single nightly doses are less effective than several doses a day[4](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-4).

**In older men and women**, 16 weeks of the nightly variant raised IGF-1 within 2 weeks, and it stayed raised for 12 weeks before drifting back toward baseline by week 16. Skin got thicker in both sexes; lean mass, insulin sensitivity, well-being and libido improved in the men only[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5).

## What dose do people use outside studies?

Community protocols use a fixed amount rather than a weight-based one. A 2026 review in Frontiers in Endocrinology recorded the pattern from a bodybuilding forum as 200 to 300 mcg under the skin once daily, typically before bedtime on an empty stomach, and labelled it self-reported online dosing, not a clinical recommendation[12](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-12). None of the studies above tested that schedule in healthy adults. The same review concludes that clinically meaningful benefits in healthy people remain uncertain, because the human evidence is limited and largely indirect[12](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-12).

For a schedule and how a dose reads on a syringe, PepVault's Dose Guide has a page at pepvault.app/lab/dosage/sermorelin; the library page, pepvault.app/peptides/sermorelin, covers its timeline and stacks.

## What side effects did the studies report?

Across the trials it was well tolerated. The most common effects were a brief facial flush and some soreness where the injection went in[1](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-1). The children's trial found no adverse changes in blood chemistry or hormones and no change in fasting glucose[2](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-2). The 6-week trial in older men saw no significant adverse effects[4](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-4). In the 16-week trial, the only one recorded was a rise in blood lipids that settled by the end of the study[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5).

## What do people who use sermorelin report?

**Commonly reported:** deeper sleep and vivid dreams within the first one to two weeks, a short warm flush after the injection, mild redness at the site, and slow changes in recovery and skin that build over months rather than days.

These are user reports, not trial results. Of the trials above, the one that asked about sleep, the 16-week trial of the close variant, found no change in sleep quality, while skin thickness did rise[5](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-5). Since the effects build slowly, the first weeks are a good time to note sleep, recovery and how the skin looks, as a baseline to compare against later.

## Is sermorelin approved today?

Not as a marketed drug. FDA's approvals database lists the two Geref applications, both discontinued, and the FDA's 2013 determination means it may approve generic versions that refer to Geref if all other requirements are met[9](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-9) [10](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-10) [11](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-11). Outside that route, the 2026 review notes that real-world use is complicated by uncertain quality and composition in unregulated peptide supply chains[12](https://pepvault.app/guides/sermorelin-dosage-in-studies#source-12).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. [PubMed 18031173](https://pubmed.ncbi.nlm.nih.gov/18031173/)
2. Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996. [PubMed 8772599](https://pubmed.ncbi.nlm.nih.gov/8772599/)
3. Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992. [PubMed 1379256](https://pubmed.ncbi.nlm.nih.gov/1379256/)
4. Vittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. [PubMed 9005976](https://pubmed.ncbi.nlm.nih.gov/9005976/)
5. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997. [PubMed 9141536](https://pubmed.ncbi.nlm.nih.gov/9141536/)
6. Wilton P et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993. [PubMed 8329825](https://pubmed.ncbi.nlm.nih.gov/8329825/)
7. Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. [PubMed 7962295](https://pubmed.ncbi.nlm.nih.gov/7962295/)
8. Rafferty B et al. Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J Endocrinol. 1985. [PubMed 2866222](https://pubmed.ncbi.nlm.nih.gov/2866222/)
9. U.S. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection, 0.5 milligrams base/vial and 1.0 milligrams base/vial, and GEREF (sermorelin acetate) injection, 0.05 milligrams base/amp, were not withdrawn from sale for reasons of safety or effectiveness. Federal Register 78 FR 14095, March 4, 2013. [federalregister.gov](https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams)
10. U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate) 0.05 mg/ampule, NDA 019863. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863)
11. U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate) 0.5 mg and 1 mg/vial, NDA 020443. [accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443)
12. Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. [PubMed 42395176](https://pubmed.ncbi.nlm.nih.gov/42395176/)
13. Sigalos JT et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. [PubMed 28830317](https://pubmed.ncbi.nlm.nih.gov/28830317/)
14. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. [PubMed 16352683](https://pubmed.ncbi.nlm.nih.gov/16352683/)
15. EGRIFTA SV (tesamorelin) prescribing information. Theratechnologies. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224)
16. UniProt P01286. Somatoliberin (growth hormone-releasing hormone), Homo sapiens. [uniprot.org](https://www.uniprot.org/uniprotkb/P01286/entry)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · Growth hormone

Guide · Growth hormone

### [Tesamorelin and visceral fat: the approved use and the trials](https://pepvault.app/guides/tesamorelin-and-visceral-fat)

Tesamorelin cut deep belly fat about 15% more than placebo in two phase 3 HIV trials, with no weight loss. The approved use, how it works, what came back.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Sermorelin Studied range: 200–500 mcg](https://pepvault.app/peptides/sermorelin)
- [CJC-1295 with DAC Studied range: 1–2 mg](https://pepvault.app/peptides/cjc-1295-with-dac)
- [Tesamorelin Studied range: 1–2 mg](https://pepvault.app/peptides/tesamorelin)

## Related guides

- Guide · Getting started

  ### [Where to inject peptides under the skin](https://pepvault.app/guides/where-to-inject-peptides)

  Where to inject subcutaneous peptides: belly, thigh or upper arm, how far from the navel, why rotating sites matters, and what is normal at the site after.

  Read the guide
- Guide · Stacks

  ### [What to take alongside each peptide](https://pepvault.app/guides/what-to-take-with-peptides)

  What to pair with each peptide, and why: glycine and vitamin C for repair, less zinc on GHK-Cu, fasting and sleep for GH peptides, protein on GLP-1s.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Sermorelin

- [Sermorelin: the full reference](https://pepvault.app/peptides/sermorelin)
- [Sermorelin dose guide](https://pepvault.app/lab/dosage/sermorelin)

### CJC-1295 with DAC

- [CJC-1295 with DAC: the full reference](https://pepvault.app/peptides/cjc-1295-with-dac)
- [CJC-1295 with DAC dose guide](https://pepvault.app/lab/dosage/cjc-1295-with-dac)

### Mixing charts

- [Sermorelin 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/sermorelin-5mg)
- [CJC-1295 with DAC 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/cjc-1295-with-dac-10mg)
- [Tesamorelin 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-2mg)
- [Tesamorelin 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tesamorelin-10mg)

### Studies

- [CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adults](https://pepvault.app/research/cjc-1295-with-dac-teichman-2006)
- [CJC-1295 with DAC changed serum protein patterns in healthy men](https://pepvault.app/research/cjc-1295-with-dac-sackmann-sala-2009)
- [CJC-1295 with DAC: trough GH up 7.5-fold, pulses kept in healthy men](https://pepvault.app/research/cjc-1295-with-dac-ionescu-2006)
- [All 5 studies](https://pepvault.app/research#cjc-1295-with-dac)

### Compared with

- [Sermorelin vs Tesamorelin](https://pepvault.app/peptides/compare/sermorelin-vs-tesamorelin)
- [Ipamorelin vs Sermorelin](https://pepvault.app/peptides/compare/ipamorelin-vs-sermorelin)
- [CJC-1295 no DAC vs Sermorelin](https://pepvault.app/peptides/compare/cjc-1295-no-dac-vs-sermorelin)
- [HGH vs Sermorelin](https://pepvault.app/peptides/compare/hgh-vs-sermorelin)
- [CJC-1295 with DAC vs CJC-1295 no DAC](https://pepvault.app/peptides/compare/cjc-1295-with-dac-vs-cjc-1295-no-dac)
- [CJC-1295 with DAC vs Ipamorelin](https://pepvault.app/peptides/compare/cjc-1295-with-dac-vs-ipamorelin)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### The Growth hormone path

- [Tesamorelin and visceral fat: the approved use and the trials](https://pepvault.app/guides/tesamorelin-and-visceral-fat)
- [HGH dosage: what the labels and the trials used](https://pepvault.app/guides/hgh-dosage-labels-and-trials)
- [Tesamorelin vs retatrutide for belly fat](https://pepvault.app/guides/tesamorelin-vs-retatrutide)
- [AOD-9604: what the human trials found](https://pepvault.app/guides/aod-9604-trials)
- [Can you drink alcohol on growth hormone peptides?](https://pepvault.app/guides/gh-peptides-and-alcohol)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Vial](https://pepvault.app/glossary/vial)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [Growth hormone (GH)](https://pepvault.app/glossary/growth-hormone)
- [GHRH](https://pepvault.app/glossary/ghrh)
- [Discontinued (Drugs@FDA)](https://pepvault.app/glossary/discontinued)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
